Posted by Michael Wonder on 09 Mar 2023
Mallinckrodt announces reimbursement approval in Japan for the Celllex extracorporeal photopheresis system for the treatment of chronic graft versus host disease
9 March 2023 - Cellex ECP is now available for reimbursement in Japan for patients who are steroid-resistant or intolerant and suffering from chronic graft versus host disease.
Mallinckrodt today announced that Japan's National Health Insurance system has approved reimbursement for the Celllex extracorporeal photopheresis system for the treatment of steroid-resistant or intolerant chronic graft versus host disease.
